Antimicrobial Activity of Non-steroidal Anti-inflammatory Drugs on Biofilm: Current Evidence and Potential for Drug Repurposing.
| Autor: | Paes Leme RC; Laboratório Especial de Microbiologia Clínica (LEMC), Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil.; Department of Infectious Diseases, Centro Universitário de Volta Redonda, Volta Redonda, Brazil., da Silva RB; Department of Internal Medicine, Hospital São Francisco de Assis, Belo Horizonte, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in microbiology [Front Microbiol] 2021 Jul 27; Vol. 12, pp. 707629. Date of Electronic Publication: 2021 Jul 27 (Print Publication: 2021). |
| DOI: | 10.3389/fmicb.2021.707629 |
| Abstrakt: | It has been demonstrated that some non-steroidal anti-inflammatory drugs (NSAIDs), like acetylsalicylic acid, diclofenac, and ibuprofen, have anti-biofilm activity in concentrations found in human pharmacokinetic studies, which could fuel an interest in repurposing these well tolerated drugs as adjunctive therapies for biofilm-related infections. Here we sought to review the currently available data on the anti-biofilm activity of NSAIDs and its relevance in a clinical context. We performed a systematic literature review to identify the most commonly tested NSAIDs drugs in the last 5 years, the bacterial species that have demonstrated to be responsive to their actions, and the emergence of resistance to these molecules. We found that most studies investigating NSAIDs' activity against biofilms were in vitro , and frequently tested non-clinical bacterial isolates, which may not adequately represent the bacterial populations that cause clinically-relevant biofilm-related infections. Furthermore, studies concerning NSAIDs and antibiotic resistance are scarce, with divergent outcomes. Although the potential to use NSAIDs to control biofilm-related infections seems to be an exciting avenue, there is a paucity of studies that tested these drugs using appropriate in vivo models of biofilm infections or in controlled human clinical trials to support their repurposing as anti-biofilm agents. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Paes Leme and da Silva.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|